Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 5 months ago) | |
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(11 months ago) | |
US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(16 days from now) | |
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(16 days from now) | |
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 3 months from now) | |
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 9 months from now) | |
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(2 years from now) | |
US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(3 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(3 years from now) | |
US8758292 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(4 years from now) | |
US8216180 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(4 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
US8439864 (Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(4 years from now) | |
US9320853 (Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(4 years from now) | |
US8827963 | ASTRAZENECA AB | Administering device with holding mechanism |
Feb, 2029
(4 years from now) | |
US8690837 | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
May, 2029
(5 years from now) | |
US8827963 (Pediatric) | ASTRAZENECA AB | Administering device with holding mechanism |
Aug, 2029
(5 years from now) | |
US8690837 (Pediatric) | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
Nov, 2029
(5 years from now) | |
US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
US8998876 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) | |
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 5 months ago) | |
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(11 months ago) | |
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(16 days from now) | |
US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(16 days from now) | |
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(6 months from now) | |
US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(1 year, 14 days from now) | |
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 3 months from now) | |
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 6 months from now) | |
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 9 months from now) | |
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(2 years from now) | |
US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(6 years from now) | |
US8895033 (Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS